CoreAge Rx advertises compounded semaglutide from $99 per month and compounded tirzepatide from $149, with no membership fee on the product pages. A program that charges for membership first may look similar in a price table while selling a different combination of services and medicine.
The comparison becomes useful when the preparation, included care and actual payment are named together. This guide follows CoreAge Rx, Ro and Noom’s published descriptions without treating their lowest figures as prices for identical treatments or as evidence that one program produces better outcomes.
Start with the medicine, then the service
CoreAge Rx’s named product pages describe US-compounded preparations, online physician evaluation and free delivery. Ro’s pricing page separates membership from FDA-approved medicines. Noom’s pricing page contains both medicine-inclusive programs and a branded-medication telehealth option that excludes the drug cost. These are meaningful product and billing differences.
A shared ingredient name does not remove the approval distinction. FDA says compounded GLP-1 preparations are not approved finished drugs and do not undergo its premarket review for safety, effectiveness and quality. The treatment guide keeps that question separate from the price of clinical access.
Compare complete bills rather than entry figures
Ro advertises $39 for the first membership month, then different continuing rates according to the selected plan; medicine is another charge. Noom’s branded telehealth option advertises $39 initially and $129 per month afterward, billed quarterly, excluding medication. Neither entry figure is a complete medication-inclusive total.
CoreAge’s $99 and $149 product rates are starting advertisements tied to different compounded medicines. Its separate policy says the selected plan may be one-time or automatically renewing, with material terms presented at purchase. The cost guide helps retain the full selected quote rather than assuming the product headline answers every financial question.
Continuing contact deserves its own description
CoreAge describes ongoing provider access; Ro’s membership names on-demand provider support. Noom describes clinical access alongside its digital program, coaching and other tools. Those features can make a service useful, but advertised availability is not a response time measured by this publication.
The relevant comparison is which professional or team handles a clinical concern, an account issue or a pharmacy question. A large feature list is not proof that every contact performs the same role. The contact guide separates those responsibilities without claiming an individual handoff was completed.
Flexibility requires the written term
CoreAge’s cancellation policy says stopping future renewals does not automatically refund an order already processed or submitted for pharmacy fulfillment. Ro offers prepaid membership choices as well as a monthly plan. Noom’s quarterly billing creates another payment interval. A monthly-looking rate does not settle those commitments.
Read the CoreAge Rx, Ro and Noom Med reviews for each offer’s context. The useful decision record holds the medicine, full bill, contact model and renewal terms together. It does not use a no-membership headline or a program feature as a clinical recommendation.
Use the offer details
Open the CoreAge Rx review, GLP-1 program index, and cost table to continue your comparison. Medical suitability should be discussed with a licensed clinician.
Documents used
Official public information reviewed October 1, 2026. Advertising describes an offer; it is not independent verification of treatment outcomes.